Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Collaborators: Reckitt Benckiser Inc.; Reckitt Benckiser LLC
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Guaifenesin; Phenylpropanolamine

Criteria

Inclusion Criteria:

• Healthy

• Non smoker

• BMI 19-29

• Normal lung function

Exclusion Criteria:

• Pregnant

• Smokers

• Any illness